Viomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin. These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was derived from the actinomycete Streptomyces puniceus.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Succinylcholine | The therapeutic efficacy of Succinylcholine can be increased when used in combination with Viomycin. |
| Metocurine iodide | The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Viomycin. |
| Gallamine triethiodide | The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Viomycin. |
| Cisatracurium | Viomycin may increase the neuromuscular blocking activities of Cisatracurium. |
| Rocuronium | The therapeutic efficacy of Rocuronium can be increased when used in combination with Viomycin. |
| Atracurium besylate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Viomycin. |
| Doxacurium | The therapeutic efficacy of Doxacurium can be increased when used in combination with Viomycin. |
| Mivacurium | The therapeutic efficacy of Mivacurium can be increased when used in combination with Viomycin. |
| Decamethonium | The therapeutic efficacy of Decamethonium can be increased when used in combination with Viomycin. |
| Metocurine | The therapeutic efficacy of Metocurine can be increased when used in combination with Viomycin. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be increased when used in combination with Viomycin. |
| Pipecuronium | The therapeutic efficacy of Pipecuronium can be increased when used in combination with Viomycin. |
| Vecuronium | The therapeutic efficacy of Vecuronium can be increased when used in combination with Viomycin. |
| Rapacuronium | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Viomycin. |
| Pyrantel | The therapeutic efficacy of Pyrantel can be increased when used in combination with Viomycin. |
| Neosaxitoxin | The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Viomycin. |
| Atracurium | The therapeutic efficacy of Atracurium can be increased when used in combination with Viomycin. |
| Gallamine | The therapeutic efficacy of Gallamine can be increased when used in combination with Viomycin. |
| Alcuronium | The therapeutic efficacy of Alcuronium can be increased when used in combination with Viomycin. |
| Tubocurarine | The therapeutic efficacy of Tubocurarine can be increased when used in combination with Viomycin. |
| Picosulfuric acid | The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Viomycin. |
| BCG vaccine | The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Viomycin. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Viomycin. |
| Cyclosporine | The risk or severity of neuromuscular blockade can be increased when Cyclosporine is combined with Viomycin. |
| Doxycycline | The risk or severity of neuromuscular blockade can be increased when Doxycycline is combined with Viomycin. |
| Lymecycline | The risk or severity of neuromuscular blockade can be increased when Lymecycline is combined with Viomycin. |
| Capreomycin | The risk or severity of neuromuscular blockade can be increased when Capreomycin is combined with Viomycin. |
| Piperacillin | The risk or severity of neuromuscular blockade can be increased when Piperacillin is combined with Viomycin. |
| Framycetin | The risk or severity of neuromuscular blockade can be increased when Framycetin is combined with Viomycin. |
| Clomocycline | The risk or severity of neuromuscular blockade can be increased when Clomocycline is combined with Viomycin. |
| Quinine | The risk or severity of neuromuscular blockade can be increased when Quinine is combined with Viomycin. |
| Vancomycin | The risk or severity of neuromuscular blockade can be increased when Vancomycin is combined with Viomycin. |
| Tigecycline | The risk or severity of neuromuscular blockade can be increased when Tigecycline is combined with Viomycin. |
| Oxytetracycline | The risk or severity of neuromuscular blockade can be increased when Oxytetracycline is combined with Viomycin. |
| Chloroquine | The risk or severity of neuromuscular blockade can be increased when Chloroquine is combined with Viomycin. |
| Demeclocycline | The risk or severity of neuromuscular blockade can be increased when Demeclocycline is combined with Viomycin. |
| Magnesium sulfate | The risk or severity of neuromuscular blockade can be increased when Magnesium sulfate is combined with Viomycin. |
| Tobramycin | The risk or severity of neuromuscular blockade can be increased when Tobramycin is combined with Viomycin. |
| Tetracycline | The risk or severity of neuromuscular blockade can be increased when Tetracycline is combined with Viomycin. |
| Gentamicin | The risk or severity of neuromuscular blockade can be increased when Gentamicin is combined with Viomycin. |
| Etacrynic acid | The risk or severity of neuromuscular blockade can be increased when Etacrynic acid is combined with Viomycin. |
| Quinidine | The risk or severity of neuromuscular blockade can be increased when Quinidine is combined with Viomycin. |
| Metacycline | The risk or severity of neuromuscular blockade can be increased when Metacycline is combined with Viomycin. |
| Netilmicin | The risk or severity of neuromuscular blockade can be increased when Netilmicin is combined with Viomycin. |
| Neomycin | The risk or severity of neuromuscular blockade can be increased when Neomycin is combined with Viomycin. |
| Minocycline | The risk or severity of neuromuscular blockade can be increased when Minocycline is combined with Viomycin. |
| Procainamide | The risk or severity of neuromuscular blockade can be increased when Procainamide is combined with Viomycin. |
| Streptomycin | The risk or severity of neuromuscular blockade can be increased when Streptomycin is combined with Viomycin. |
| Colistimethate | The risk or severity of neuromuscular blockade can be increased when Colistimethate is combined with Viomycin. |
| Kanamycin | The risk or severity of neuromuscular blockade can be increased when Kanamycin is combined with Viomycin. |
| Clindamycin | The risk or severity of neuromuscular blockade can be increased when Clindamycin is combined with Viomycin. |
| Dantrolene | The risk or severity of neuromuscular blockade can be increased when Dantrolene is combined with Viomycin. |
| Rolitetracycline | The risk or severity of neuromuscular blockade can be increased when Rolitetracycline is combined with Viomycin. |
| Magnesium oxide | The risk or severity of neuromuscular blockade can be increased when Magnesium oxide is combined with Viomycin. |
| Magnesium cation | The risk or severity of neuromuscular blockade can be increased when Magnesium cation is combined with Viomycin. |
| Paromomycin | The risk or severity of neuromuscular blockade can be increased when Paromomycin is combined with Viomycin. |
| Lincomycin | The risk or severity of neuromuscular blockade can be increased when Lincomycin is combined with Viomycin. |
| Ribostamycin | The risk or severity of neuromuscular blockade can be increased when Ribostamycin is combined with Viomycin. |
| Geneticin | The risk or severity of neuromuscular blockade can be increased when Geneticin is combined with Viomycin. |
| Apramycin | The risk or severity of neuromuscular blockade can be increased when Apramycin is combined with Viomycin. |
| Gentamicin C1a | The risk or severity of neuromuscular blockade can be increased when Gentamicin C1a is combined with Viomycin. |
| Neamine | The risk or severity of neuromuscular blockade can be increased when Neamine is combined with Viomycin. |
| Arbekacin | The risk or severity of neuromuscular blockade can be increased when Arbekacin is combined with Viomycin. |
| Puromycin | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Puromycin. |
| Magnesium hydroxide | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium hydroxide. |
| Magnesium trisilicate | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium trisilicate. |
| Magnesium chloride | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium chloride. |
| Magnesium acetate tetrahydrate | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium acetate tetrahydrate. |
| Magnesium carbonate | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium carbonate. |
| Magnesium citrate | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium citrate. |
| Magnesium glycinate | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium glycinate. |
| Magnesium Aluminum Silicate | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium Aluminum Silicate. |
| Dihydrostreptomycin | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Dihydrostreptomycin. |
| Hygromycin B | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Hygromycin B. |
| Sisomicin | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Sisomicin. |
| Plazomicin | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Plazomicin. |
| Magnesium silicate | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium silicate. |
| Penimepicycline | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Penimepicycline. |
| Magnesium aspartate | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium aspartate. |
| Isepamicin | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Isepamicin. |
| Magnesium gluconate | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium gluconate. |
| Magnesium orotate | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium orotate. |
| Magnesium phosphate | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium phosphate. |
| Magnesium acetate | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium acetate. |
| Magnesium stearate | The risk or severity of neuromuscular blockade can be increased when Viomycin is combined with Magnesium stearate. |
| Colistin | The risk or severity of neuromuscular blockade can be increased when Colistin is combined with Viomycin. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Viomycin is combined with Botulinum toxin type B. |
| Botulinum toxin type A | The therapeutic efficacy of Botulinum toxin type A can be increased when used in combination with Viomycin. |
| Nicotine | The risk or severity of adverse effects can be increased when Viomycin is combined with Nicotine. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Viomycin is combined with Mecamylamine. |
| Pentolinium | The risk or severity of adverse effects can be increased when Viomycin is combined with Pentolinium. |
| Trimethaphan | The risk or severity of adverse effects can be increased when Viomycin is combined with Trimethaphan. |
| Hexamethonium | The risk or severity of adverse effects can be increased when Viomycin is combined with Hexamethonium. |
| Cyclopentamine | The risk or severity of adverse effects can be increased when Viomycin is combined with Cyclopentamine. |
| Dicoumarol | The risk or severity of bleeding can be increased when Viomycin is combined with Dicoumarol. |
| Phenindione | The risk or severity of bleeding can be increased when Viomycin is combined with Phenindione. |
| Warfarin | The risk or severity of bleeding can be increased when Viomycin is combined with Warfarin. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Viomycin is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Viomycin is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of bleeding can be increased when Viomycin is combined with 4-hydroxycoumarin. |